Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

30%

3 trials in Phase 3/4

Results Transparency

56%

5 of 9 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 4

3(37.5%)

Phase 2

2(25.0%)

N/A

2(25.0%)

Phase 1

1(12.5%)

8Total

Phase 4(3)

Phase 2(2)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT02677701Phase 4Completed

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

Role: collaborator

NCT02781610Phase 4Completed

Standardized Treatment of Pulmonary Exacerbations II

Role: collaborator

NCT00676169Completed

The EPIC Observational Study

Role: lead

NCT01349192Phase 2Terminated

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

Role: collaborator

NCT00431964Phase 4Completed

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

Role: lead

NCT00097773Phase 2Completed

Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis

Role: collaborator

NCT01078740Completed

Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects

Role: lead

NCT00709280Not ApplicableCompleted

Infant Study of Inhaled Saline in Cystic Fibrosis

Role: lead

NCT00546663Not ApplicableCompleted

Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis

Role: lead

NCT00219882Phase 1Completed

Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis

Role: collaborator

All 10 trials loaded